Jardiance empagliflozin regulatory update

Eli Lilly and Boehringer said FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 12-11 that data from

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE